Viridian Therapeutics Inc (VRDN)

NASDAQ
Currency in USD
15.88
+0.21(+1.34%)
Closed·
After Hours
15.93+0.05(+0.31%)
·
VRDN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
VRDN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.1815.93
52 wk Range
9.9027.20
Key Statistics
Edit
Prev. Close
15.67
Open
15.22
Day's Range
15.18-15.93
52 wk Range
9.9-27.2
Volume
708.75K
Average Vol. (3m)
869.05K
1-Year Change
20.76%
Book Value / Share
5.1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VRDN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
38.31
Upside
+141.26%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Viridian Therapeutics Inc News & Analysis

Show more

Viridian Therapeutics Inc Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics Inc SWOT Analysis


Beyond TED
Explore Viridian's expansion into FcRn-mediated diseases with VRDN-008, potentially opening new market opportunities beyond thyroid eye disease treatment
Analyst Optimism
Consensus "Strong Buy" recommendation with price targets ranging from $19 to $61, averaging around $38, reflecting market confidence in VRDN's potential
Financial Strength
With over $630 million in cash, Viridian is well-positioned to fund operations into 2027, supporting ongoing clinical programs and potential launch
Promising TED Treatment
Viridian's veligrotug shows compelling long-term efficacy for thyroid eye disease, with 70% of responders maintaining results at week 52
Read full SWOT analysis

Viridian Therapeutics Inc Earnings Call Summary for Q1/2024

  • Phase 3 trial for VRDN-001 in active TED completed enrollment; top-line results expected September 2024; BLA filing planned for H2 2025
  • Subcutaneous VRDN-003 program to start pivotal trials mid-year after positive FDA Type C meeting
  • IND filing for VRDN-006 by year-end; non-human primate data for VRDN-008 due H2 2024
  • $613 million cash position provides runway into H2 2026; company on track with clinical timelines and regulatory milestones
  • CEO highlights underpenetrated TED market potential; subcutaneous delivery method seen as game-changing for patient care
Last Updated: 05/09/2024, 01:26 PM
Read Full Transcript

Compare VRDN to Peers and Sector

Metrics to compare
VRDN
Peers
Sector
Relationship
P/E Ratio
−5.3x−4.6x−0.5x
PEG Ratio
0.35−0.020.00
Price / Book
3.1x2.4x2.6x
Price / LTM Sales
4,290.3x10.8x3.1x
Upside (Analyst Target)
142.5%182.7%50.4%
Fair Value Upside
Unlock1.2%8.7%Unlock

Analyst Ratings

14 Buy
2 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 38.31
(+141.26% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-0.87 / -0.98
Revenue / Forecast
70.00K / 52.09K
EPS Revisions
Last 90 days

VRDN Income Statement

People Also Watch

98.73
INSM
+1.91%
65.07
ACLS
-5.57%
32.76
XENE
-0.12%
67.19
MRVL
-3.52%

FAQ

What Is the Viridian Therapeutics (VRDN) Stock Price Today?

The Viridian Therapeutics stock price today is 15.88

What Stock Exchange Does Viridian Therapeutics Trade On?

Viridian Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Viridian Therapeutics?

The stock symbol for Viridian Therapeutics is "VRDN."

What Is the Viridian Therapeutics Market Cap?

As of today, Viridian Therapeutics market cap is 1.29B.

What Is Viridian Therapeutics's Earnings Per Share (TTM)?

The Viridian Therapeutics EPS (TTM) is -3.33.

When Is the Next Viridian Therapeutics Earnings Date?

Viridian Therapeutics will release its next earnings report on Aug 06, 2025.

From a Technical Analysis Perspective, Is VRDN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Viridian Therapeutics Stock Split?

Viridian Therapeutics has split 2 times.

How Many Employees Does Viridian Therapeutics Have?

Viridian Therapeutics has 143 employees.

What is the current trading status of Viridian Therapeutics (VRDN)?

As of Jun 14, 2025, Viridian Therapeutics (VRDN) is trading at a price of 15.88, with a previous close of 15.67. The stock has fluctuated within a day range of 15.18 to 15.93, while its 52-week range spans from 9.90 to 27.20.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.